SOTIO is a biotechnology company developing a new Active Cellular Immunotherapy (“ACI”) based on activated dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO continues to develop new therapies to address unmet medical needs using its immunotherapy platform and proprietary cell-based technologies.
In SOTIO’s state-of-the-art immunotherapy treatment manufacturing facility, located in Prague, Czech Republic, the company focuses on understanding the role of dendritic cells in the therapeutic activations of the body’s immune system and its effectiveness in treating cancer and autoimmune diseases.
SOTIO has an active presence in Europe, the United States, China and Russia. Due to its central location, SOTIO’s GMP (Good Manufacturing Practice) certified cell therapy manufacturing facility in Prague can manufacture and supply immunotherapy treatment to meet the needs of its clinical development programs in both Europe and the United States. In Beijing, China, SOTIO manufactures immunotherapy treatment in its dedicated production facility, built in 2014. SOTIO’s Beijing facility manufactures and supplies immunotherapy treatment for cooperative research projects conducted by leading Chinese hospitals.
SOTIO’s philosophy of research into ACI for the treatment of cancer and autoimmune diseases is based on the following:
- Use of SOTIO’s proprietary ACI-MAP (Active Cellular Immunotherapy Multiple Antigen Presentation) technology. Following this proprietary ACI-MAP method, the patient’s own dendritic cells, are activated by a broad range of tumor antigens that induce a complex immune response.
- Concept of combination therapy. While immunotherapy alone is an area focusing on early stage cancer patients, SOTIO’s ACI-MAP technology is also being investigated in patients with advanced cancer in combination with multiple treatments modalities in a synergistic way to control disease progression.
- Long-term boosting of the immune response. SOTIO’s ACI requires patients to be treated at regular intervals (every 2-6 weeks) for up to a year or more. This concept is supported by preclinical evidence and clinical observations that one leukapheresis yields sufficient DCVAC product for long term immune boosting which leads to long-term stimulation of the patient’s immune system.
Combinations of the above-mentioned principles are currently being tested in multiple clinical trials. The outcome is expected to be more effective treatment involving Active Cellular Immunotherapy to be used for those patients who otherwise have limited alternative treatment options.
SOTIO’s clinical program currently focuses on developing a new ACI for the treatment of prostate cancer, which we call DCVAC/PCa. Phase II clinical trials, involving several hundred patients with prostate cancer at various stages are ongoing.
In May 2014, SOTIO launched its Global Phase III clinical trial, called the VIABLE Study, to investigate the safety and efficacy of DCVAC/PCa in patients with metastatic castrate resistant prostate cancer. The VIABLE Study is expected to enroll more than one thousand patients worldwide.
In October 2013, SOTIO launched three Phase II clinical trials to assess the safety and efficacy of its investigational ACI when combined with the standard of care treatments in patients with epithelial ovarian cancer (DCVAC/OvCa). These clinical trials assessing combination treatments with DCVAC/OvCa, take place at investigational sites in the Czech Republic, Germany and Poland, and include patients at various stages of their disease, with different response to standard therapies.
In December 2014, SOTIO launched Phase I/II clinical trial to assess the use of active cellular immunotherapy (DCVAC/LuCa). This clinical trial will focus on determining, the safety and efficacy of the DCVAC/LuCa in combination with standard chemotherapy treatment for patients with advanced metastasis of non-small cell lung carcinoma (NSCLC).
Part of PPF Group
SOTIO is a part of PPF Group, one of the largest investment groups in Central and Eastern Europe (please see www.ppf.eu).